Evidence map›Paper›PMID 35829979›Full record

ReviewCardiovascular drugs and therapy2024

The Cost of Breaking Even: a Perspective on the Net Clinical Impact of Adding Aspirin to Antithrombotic Therapies in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.

Jeffrey Triska, Faris Haddadin, Luai Madanat, Ahmad Jabri, Marilyne Daher, Yochai Birnbaum, Hani Jneid

Abstract readReview
PubMed Publisher
In one paragraph

Review in Cardiovascular drugs and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 85% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Jeffrey TriskaDepartment of Medicine, Baylor College of Medicine, Houston, TX, USA. Jeffrey.Triska@bcm.edu.ORCID 0000-0003-4476-7994
Faris HaddadinDepartment of Medicine, Section of Cardiology, Baylor College of Medicine, Houston, TX, USA.
Luai MadanatDepartment of Medicine, William Beaumont School of Medicine, Royal Oak, MI, USA.
Ahmad JabriHeart and Vascular Center, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH, USA.
Marilyne DaherDepartment of Medicine, Baylor College of Medicine, Houston, TX, USA.
Yochai BirnbaumDepartment of Medicine, Section of Cardiology, Baylor College of Medicine, Houston, TX, USA.
Hani JneidDepartment of Medicine, Section of Cardiology, University of Texas Medical Branch, Galveston, TX, USA.
Baylor College of Medicine · USBeaumont Hospital, Royal Oak · USMetroHealth Medical Center · USThe University of Texas Medical Branch at Galveston · US

Funding

John S. Dunn Foundation B2017/BMD-3738
6 · The paper itself

Abstract

purposeOutcomes from randomized controlled trials (RCTs) inform the latest recommendations on percutaneous coronary intervention (PCI) management of a short period of oral anticoagulation (OAC), a P2Y

methodsWe examined and summarized the outcomes of bleeding and major adverse cardiac events (MACEs) from RCTs and meta-analyses, published between 2013 and 2022, comparing therapy with OAC and a P2Y

resultsData comparing dual therapy with OAC and a P2Y

conclusionThe addition of aspirin to OAC and a P2Y

Indexed as

AspirinAtrial FibrillationDrug Therapy, CombinationHemorrhagePercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsRandomized Controlled Trials as TopicAnticoagulantsCoronary Artery DiseaseFibrinolytic AgentsHumansRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeAnticoagulantsAspirinFibrinolytic AgentsPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsAcute coronary syndromeDual antithrombotic therapyMajor bleedingPercutaneous coronary interventionStent thrombosisTriple antithrombotic therapy

Identifiers

PMID35829979
OpenAlexW4285087203

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.